Serina Therapeutics Statistics
Total Valuation
SER has a market cap or net worth of $56.35 million. The enterprise value is $58.07 million.
Important Dates
The last earnings date was Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
SER has 9.39 million shares outstanding. The number of shares has decreased by -7.43% in one year.
| Current Share Class | 9.39M |
| Shares Outstanding | 9.39M |
| Shares Change (YoY) | -7.43% |
| Shares Change (QoQ) | +5.85% |
| Owned by Insiders (%) | 29.12% |
| Owned by Institutions (%) | 6.74% |
| Float | 3.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.59 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 18.39 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.40
| Current Ratio | 0.40 |
| Quick Ratio | 0.24 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.43 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -86.73% |
| Return on Capital (ROIC) | -257.92% |
| Revenue Per Employee | $287,045 |
| Profits Per Employee | -$668,104 |
| Employee Count | 11 |
| Asset Turnover | 0.39 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.50% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -61.50% |
| 50-Day Moving Average | 5.70 |
| 200-Day Moving Average | 8.33 |
| Relative Strength Index (RSI) | 49.50 |
| Average Volume (20 Days) | 43,709 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SER had revenue of $3.16 million and -$7.35 million in losses. Loss per share was -$1.28.
| Revenue | 3.16M |
| Gross Profit | -2.86M |
| Operating Income | -11.26M |
| Pretax Income | -890,146 |
| Net Income | -7.35M |
| EBITDA | -11.11M |
| EBIT | -11.26M |
| Loss Per Share | -$1.28 |
Full Income StatementBalance Sheet
The company has $3.19 million in cash and $11.67 million in debt, giving a net cash position of -$8.48 million or -$0.90 per share.
| Cash & Cash Equivalents | 3.19M |
| Total Debt | 11.67M |
| Net Cash | -8.48M |
| Net Cash Per Share | -$0.90 |
| Equity (Book Value) | -13.83M |
| Book Value Per Share | -1.55 |
| Working Capital | -8.09M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$12.43 million and capital expenditures -$87,015, giving a free cash flow of -$12.52 million.
| Operating Cash Flow | -12.43M |
| Capital Expenditures | -87,015 |
| Free Cash Flow | -12.52M |
| FCF Per Share | -$1.33 |
Full Cash Flow StatementMargins
Gross margin is -90.70%, with operating and profit margins of -356.51% and -232.75%.
| Gross Margin | -90.70% |
| Operating Margin | -356.51% |
| Pretax Margin | -234.46% |
| Profit Margin | -232.75% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |